Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
103 hedge funds and large institutions have $44.5M invested in Carisma Therapeutics in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 24 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 25
0.62% less ownership
Funds ownership: 1.91% → 1.29% (-0.62%)
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
2% less funds holding
Funds holding: 105 → 103 (-2)
24% less call options, than puts
Call options by funds: $2.09M | Put options by funds: $2.75M
85% less capital invested
Capital invested by funds: $305M → $44.5M (-$261M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.08M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$3.01M |
| 3 |
HF
HRT Financial
New York
|
+$1.7M |
| 4 |
Jane Street
New York
|
+$1.55M |
| 5 |
Morgan Stanley
New York
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$23.2M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$9.16M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$3.29M |
| 4 |
Millennium Management
New York
|
-$2.77M |
| 5 |
Citigroup
New York
|
-$2.17M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$960 | +20 | New |
|
CARM Hedge Fund Activity: Q3 2021 in Review
103 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2021, worth a combined $44.5M — down 85% from $305M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CARM and 23 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 39 added.
The largest buyer was Vanguard Group, adding an estimated $4.08M. The largest seller was State Street, cutting an estimated $23.2M.
- 103 institutional investors held Carisma Therapeutics (CARM) as of Q3 2021, down from 105 in Q2 2021.
- Funds reported $44.5M of Carisma Therapeutics stock for Q3 2021, down 85% quarter-over-quarter.
- 23 funds opened new Carisma Therapeutics positions in Q3 2021 and 24 closed out, a net change of -1 holder.
- The largest Carisma Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $4.08M added.
- The largest Carisma Therapeutics seller in Q3 2021 was State Street, an estimated $23.2M sold.
Based on aggregated 13F filings for Q3 2021.